Seres Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.31 million compared to USD 3.44 million a year ago. Net loss was USD 47.85 million compared to USD 60 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.49 a year ago.
For the nine months, revenue was USD 126.26 million compared to USD 6.15 million a year ago. Net loss was USD 72.48 million compared to USD 181.36 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 1.77 a year ago.